natgillin/translations-raw huggingface dataset:
Neupro is indicated for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (RLS) in adults.
Zdravilo Neupro je indicirano za simptomatsko zdravljenje zmerne do hude idiopatične oblike sindroma nemirnih nog (RLS – Restless Legs Syndrome) pri odraslih.
Neupro is used on its own in early-stage disease, or in combination with levodopa (another medicine used in Parkinson’s disease) at any stage of the disease, including the later stages when levodopa starts becoming less effective; moderate to severe restless legs syndrome, a disorder where the patient has uncontrollable urges to move the limbs to stop uncomfortable, painful or odd sensations in the body, usually at night.
Zdravilo Neupro se uporablja kot samostojno zdravilo v zgodnji fazi bolezni ali v kombinaciji z levodopo (drugim zdravilom za zdravljenje Parkinsonove bolezni) v kateri koli fazi bolezni, vključno v poznih fazah, ko začne učinek levodope popuščati; zmernega do hudega sindroma nemirnih nog, tj. motnje, pri kateri ima bolnik nenadzorovano potrebo po premikanju okončin, da bi se znebil neprijetnih, bolečih ali nenavadnih občutkov v telesu, običajno ponoči.
Neupro is used to treat Restless Legs Syndrome (RLS) in adults that can be associated with discomfort in your legs or arms, urge to move around, sleep disturbance, tiredness or sleepiness during the day.
Zdravilo Neupro se uporablja za zdravljenje sindroma nemirnih nog (Restless Legs Syndrome - RLS) pri odraslih, ki je lahko povezan z nelagodjem v vaših nogah ali rokah, s potrebo po premikanju, motnjami spanja, utrujenostjo ali zaspanostjo čez dan.
Neupro is used to treat the signs and symptoms of Parkinson’s disease in adults either alone or in combination with the medicine called levodopa.
Zdravilo Neupro se uporablja za zdravljenje znakov in simptomov Parkinsonove bolezni pri odraslih bodisi kot samostojno zdravljenje bodisi v kombinaciji z zdravilom imenovanim L-dopa.
Neupro is used to treat:
Zdravilo Neupro se uporablja za zdravljenje:
Neupro may cause abnormal thinking and behaviour.
Zdravilo Neupro lahko povzroči nenormalno mišljenje in vedenje.
Neupro may decrease blood pressure when you stand up; this effect may worsen by the medicine used to lower blood pressure. take sedating medicines (for example benzodiazepines, medicines used to treat mental conditions or depression) while you are using Neupro.
Zdravilo Neupro lahko zniža krvni tlak, ko stojite jemati sedative, na primer benzodiazepin (zdravila za zdravljenje duševnih motenj ali depresije)
Neupro may decrease blood pressure when you stand up; this effect may worsen by the medicine used to lower blood pressure. take sedating medicines (for example benzodiazepines, medicines used to treat mental conditions or depression) while you are using Neupro.
Zdravilo Neupro lahko zniža krvni tlak, ko stojite; ta učinek se lahko poslabša ob jemanju zdravila za zniževanje krvnega tlaka jemati sedative, na primer benzodiazepin (zdravila za zdravljenje duševnih motenj ali depresije)
Neupro may decrease blood pressure when you stand up; this effect may worsen by the medicine used to lower blood pressure. take sedating medicines (for example benzodiazepines, medicines used to treat mental conditions or depression) while you are using Neupro.
Zdravilo Neupro lahko zniža krvni tlak, ko stojite; ta učinek se lahko poslabša ob jemanju zdravila za zniževanje krvnega tlaka jemati sedative, na primer benzodiazepin (zdravila za zdravljenje duševnih motenj ali depresije).
Neupro may make you feel very drowsy, and you may fall asleep very suddenly.
Zaradi zdravila Neupro ste lahko zelo dremavi in lahko povsem nenadno zaspite.
Neupro should not be used by children because its safety and efficacy has not been established in children.
Zdravila Neupro ne smete uporabiti pri otrocih, ker njegova varnost in učinkovitost pri otrocih nista bili dokazani.
Neupro was more effective than placebo in treating Parkinson’s disease.
Zdravilo Neupro je bilo pri zdravljenju Parkinsonove bolezni učinkovitejše od placeba.
Neupro with food, drink and alcohol
Zdravilo Neupro skupaj s hrano, pijačo in alkoholom
Neuraceq 300 MBq/mL solution for injection Florbetaben (18F)
Neuraceq 300 MBq/ml raztopina za injiciranje [18F]florbetaben
Neuraceq can only be obtained with a prescription, and PET scans with Neuraceq should only be requested by doctors experienced in the management of patients with diseases such as Alzheimer’s and other dementias.
Izdaja zdravila Neuraceq je le na recept, PET-preiskave z zdravilom Neuraceq pa lahko naročijo samo zdravniki, ki imajo izkušnje z zdravljenjem bolnikov z boleznimi, kot so Alzheimerjeva bolezen in druge demence.
Neuraceq contains the active substance florbetaben (18F).
Zdravilo Neuraceq vsebuje zdravilno učinkovino [18F]florbetaben.
Neuraceq has no known influence on the ability to drive and use machines.
Ni znano, da bi imelo zdravilo Neuraceq kakršen koli vpliv na sposobnost vožnje in upravljanja s stroji.
Neuraceq has no known influence on the ability to drive and use machines.
Vpliv zdravila Neuraceq na sposobnost vožnje in upravljanja s stroji ni znan.
Neuraceq images should only be interpreted by readers trained in the interpretation of PET images with florbetaben (18F).
Slike z zdravilom Neuraceq smejo interpretirati le odčitovalci, usposobljeni za interpretacijo PET- posnetkov s [18F]florbetabenom.
Neuraceq is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of β-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment.
Zdravilo Neuraceq je radiofarmak, indiciran za slikanje gostote β-amiloidnih nevritičnih leh s pozitronsko emisijsko tomografijo (PET) v možganih odraslih bolnikov s kognitivno motnjo, pri katerih se ugotavljajo Alzheimerjeva bolezen (AB) in drugi vzroki kognitivne motnje.
Neuraceq is for intravenous use and for multidose use.
Zdravilo Neuraceq je predvideno za intravensko uporabo in za večodmerno uporabo.
Neuraceq is used during brain scans in patients with memory problems so that doctors can see whether or not they have significant amounts of β‑amyloid plaques in the brain. β-amyloid plaques are deposits sometimes present in the brain of people with memory problems caused by dementia (such as Alzheimer’s disease, Lewy-body dementia and Parkinson’s disease dementia) and also in the brain of some elderly people with no symptoms.
Zdravilo Neuraceq se uporablja med možganskimi preiskavami pri bolnikih, ki imajo težave s spominom, da lahko zdravniki ugotovijo, ali imajo morda v možganih večje količine β‑amiloidnih leh. β-amiloidne lehe so obloge, ki so včasih prisotne v možganih oseb, ki imajo težave s spominom zaradi demence (kot so na primer Alzheimerjeva bolezen, demenca z Lewyjevimi telesci in demenca pri Parkinsonovi bolezni), ter tudi v možganih nekaterih starejših oseb, ki nimajo nobenih simptomov.
Neuraceq must not be used after the expiry date which is stated on the box, shield label or vial label after EXP.
Zdravila Neuraceq ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli, nalepki zaščite ali nalepki viale poleg oznake EXP.
Neuraceq should be used in conjunction with a clinical evaluation.
Zdravilo Neuraceq je treba uporabiti skupaj s kliničnim vrednotenjem.
Neuralgia
nevralgija
Neuralgia, peripheral neuropathy, headache
nevralgija, periferna nevropatija, glavobol
Neuralgia, transient thrombocytopenia.
Nevralgija, prehodna trombocitopenija.
neuralgic pain in the leg
nevralgične bolečine v nogah
Neuritis (inflammation of nerves)
záchvaty, neuritída (zápal nervov).
Neuritis: PT “Neuritis”
Nevritis: PI „Nevritis“
Neurobehavioural functions of offspring were not affected.
Obnašanje mladičev, vezano na njihove živčne in možganske funckije, ni bilo moteno.
NeuroBloc 5000 U/ml solution for injection IM
NeuroBloc 5.000 E/ml raztopina za injiciranje i.m.
NeuroBloc botulinum toxin type B
NeuroBloc botulinski toksin vrste B
NeuroBloc has been compared with placebo (a dummy treatment) in four studies involving a total of 392 adults with cervical dystonia.
Zdravilo NeuroBloc so primerjali s placebom (zdravilom brez zdravilne učinkovine) v štirih študijah, ki so vključevale skupaj 392 odraslih s cervikalno distonijo.
NeuroBloc is a solution for injection that contains the active substance botulinum toxin type B (5000 units [U] per millilitre).
Zdravilo NeuroBloc je raztopina za injiciranje, ki vsebuje zdravilno učinkovino botulinski toksin vrste B (5 000 enot [e] na mililiter).
NeuroBloc is not recommended in children aged 0-18 years until further data become available.
Zdravilo NeuroBloc se ne priporoča pri otrocih, starih 0-18 let, dokler ne bo na voljo več podatkov.
NeuroBloc is not to be used in children aged 0-18 years.
Pri otrocih, starih 0-18 let, se zdravilo NeuroBloc ne sme uporabljati.
NeuroBloc is only used in hospitals, by a doctor who is familiar with and has experience in the treatment of cervical dystonia and in the use of botulinum toxins.
Zdravilo NeuroBloc se sme dajati le v bolnišnici, in sicer ga lahko daje le zdravnik, ki je seznanjen s cervikalno distonijo in ima izkušnje z njenim zdravljenjem ter uporabo botulinskih toksinov.
NeuroBloc is used to treat cervical dystonia.
Zdravilo NeuroBloc se uporablja za zdravljenje cervikalne distonije.
NeuroBloc must not be used in patients with other neuromuscular (nerve and muscle) disorders.
Zdravila ne smejo uporabljati bolniki z drugimi nevromuskularnimi (živčnimi in mišičnimi) obolenji.
NeuroBloc should not be used during pregnancy unless the clinical condition of the woman requires treatment with Botulinum Toxin Type B.
Zdravila NeuroBloc ne smete uporabljati pri nosečnicah, razen če klinično stanje nosečnice zahteva zdravljenje z botulinskim toksinom vrste B.
NeuroBloc should not be used in people who may be hypersensitive (allergic) to botulinum toxin or any of the other ingredients.
Zdravila NeuroBloc ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) botulinski toksin ali katero koli drugo sestavino zdravila.
NeuroBloc treatment starts with 10,000 U, divided into equal dosess and injected directly into the two to four muscles in the neck and shoulders that are most affected.
Začetni odmerek zdravila NeuroBloc je 10 000 enot in ga je treba razdeliti v enake odmerke, ki se vbrizgajo neposredno v dve do štiri najbolj prizadete mišice vratu in ramen.
Neuroendocrine tumours of gastrointestinal or lung origin
Nevroendokrini tumorji gastrointestinalnega ali pljučnega izvora
Neurofilament abnormalities, myelination and cell enlargement were all improved by the treatment, although dysplastic neuronal features persisted, and there were only modest changes in dendritic spine density and length.
Zdravljenje je izboljšalo nepravilnosti nevrofilamentov, mielinizacijo in povečevanje celic, ni pa odpravilo displastičnih lastnosti nevronov in je le malo vplivalo na gostoto in dolžino dendritskih trnov.
Neuroleptic
Akatizija6
Neuroleptic
maligni sindrom
NEUROLEPTIC
NERVOLEPTIKI
Neuroleptic
Nevroleptični
Neuroleptic malignant
halucinacije
Neuroleptic malignant
maligni sindrom
Neuroleptic Malignant Syndrome
maligni nevroleptični sindrom s
neuroleptic malignant syndrome (confusion, reduced or loss of consciousness, high fever, and severe muscle stiffness)
nevroleptični maligni sindrom (zmedenost, zmanjšana stopnja zavesti ali nezavest, visoka telesna temperatura, in huda okorelost mišic)
neuroleptic malignant syndrome (confusion, reduced or loss of consciousness, high fever, and severe muscle stiffness), sudden loss of blood supply to brain (stroke or "mini" stroke), unresponsive to stimuli, loss of consciousness, low level of consciousness, balance disorder
nevroleptični maligni sindrom (zmedenost, zmanjšana stopnja zavesti ali nezavest, visoka telesna temperatura, in huda okorelost mišic), nenadna prekinitev prekrvavitve možganov (kap ali "mini" kap), neodzivnost na dražljaje, zmanjšana stopnja zavesti, motnje ravnotežja
Neuroleptic malignant syndrome (NMS)
maligni nevroleptični sindrom
Neuroleptic Malignant Syndrome (NMS) is a rare severe reaction to medicines used to treat disorders of the nervous system.
nevroleptični maligni sindrom (NMS) je redka huda reakcija na zdravila za zdravljenje centralnega živčnega sistema.
Neuroleptic Malignant Syndrome (NMS) is a serious but rare reaction to certain medicines, and may occur especially when Entacapone Orion and other medicines to treat Parkinson’s disease are suddenly stopped or the dose is suddenly reduced.
Nevroleptični maligni sindrom (NMS) je resna, vendar redka reakcija na določena zdravila.
Neuroleptic Malignant Syndrome (NMS), characterised by hyperthermia, muscle rigidity, autonomic instability, altered consciousness, and elevated serum creatine phosphokinase levels has been reported to occur with paliperidone.
Poročali so, da se pri uporabi paliperidona lahko pojavi nevroleptični maligni sindrom (NMS), za katerega so značilni hipertermija, mišična rigidnost, avtonomna nestabilnost, spremenjeno stanje zavesti in zvečanje koncentracije kreatinin kinaze v serumu.
Neuroleptic malignant syndrome (see section
nevroleptični maligni sindrom (glejte poglavje 4.4)12
Neuroleptic malignant syndrome (see section 4.4)
nevroleptični maligni sindrom (glejte
Neuroleptic malignant syndrome (see section 4.4) 12 Discontinuation
Nevroleptični maligni sindrom (glejte poglavje 4.4)12 Odtegnitveni simptomi7, 12
Neuroleptic malignant syndrome (see section 4.4) 12 Discontinuation symptoms7, 12
Nevroleptični maligni sindrom (glejte poglavje 4.4)12 Odtegnitveni simptomi7, 12
Neuroleptic malignant syndrome (see section 4.4)12
Nevroleptični maligni sindrom (glejte
Neuroleptic malignant syndrome (see section 4.4)12
nevroleptični maligni sindrom (glejte poglavje 4.4)12
Neuroleptic malignant syndrome (see section 4.4)12 Discontinuation symptoms7, 12
Nevroleptični maligni sindrom (glejte poglavje 4.4) 12 Odtegnitveni simptomi7, 12
Neuroleptic malignant syndrome (see section 4.4)12 Discontinuation symptoms7, 12
Nevroleptični maligni sindrom (glejte poglavje 4.4)12 Odtegnitveni simptomi7, 12
Neuroleptic malignant syndrome (see section 4.4)12 Discontinuation symptoms7,12
Nevroleptični maligni sindrom (glejte poglavje 4.4)
Neuroleptic malignant syndrome (see section 4.4)12 Discontinuation symptoms7,12
Nevroleptični maligni sindrom (glejte poglavje 4.4)12 Odtegnitveni simptomi7,12
Neuroleptic malignant syndrome (see section 4.4)12Discontinuat ion symptoms7, 12
Nevroleptični maligni sindrom (glejte poglavje 4.4)12 Odtegnitveni simptomi7, 12
Neuroleptic Malignant Syndrome Symptom Complex
Maligni nevroleptični sindrom s kompleksom simptomov
neuroleptic malignant syndrome, cerebral ischaemia, unresponsive to stimuli, loss of consciousness, depressed level of
nevroleptični maligni sindrom, možganska ishemija, neodzivnost na dražljaje, izguba zavesti, zmanjšana stopnja zavesti,
neuroleptic malignant syndrome, cerebral ischaemia, unresponsive to stimuli, loss of consciousness, depressed level of consciousness, diabetic comae, balance disorder, coordination abnormale, head titubatione
nevroleptični maligni sindrom, možganska ishemija, neodzivnost na dražljaje, izguba zavesti, zmanjšana stopnja zavesti, diabetična komae, motnje ravnotežja, motnje v koordinacijie, tresenje glavee
neuroleptic malignant syndrome, cerebral ischaemia, unresponsive to stimulic, loss of consciousness, depressed level of consciousnessc, diabetic comac balance disorder, coordination abnormal, head titubationc
nevroleptični maligni sindrom, možganska ishemija, neodzivnost na dražljajec, izguba zavesti, zmanjšana stopnja zavestic, diabetična komac, motnje ravnotežja, motnje v koordinaciji, tresenje glavec
Neuroleptic Malignant Syndrome, characterised by hyperthermia, muscle rigidity, autonomic instability, altered consciousness and elevated serum creatine phosphokinase levels, has been reported to occur with antipsychotics including lurasidone.
Pri zdravljenju z antipsihotiki, vključno z lurasidonom, so poročali o malignem nevroleptičnem sindromu, značilnem po hipertermiji, mišični okorelosti, avtonomni nestabilnosti, spremenjenem stanju zavesti in zvišani vrednosti kreatin-kinaze v serumu.
NEUROLEPTICS
NEVROLEPTIKI
Neuroleptics (e.g. phenothiazines, sertindole, sultopride, chlorpromazine, haloperidol, mesoridazine, pimozide, or thioridazine), antidepressive agents.
nevroleptike (npr. fenotiazine, sertindol, sultoprid, klorpromazin, haloperidol, mesoridazin, pimozid ali tioridazin), antidepresive.
Neuroleptics (e.g. phenothiazines, sertindole, sultopride, chlorpromazine, haloperidol, mesoridazine, pimozide, or thioridazine), antidepressive medicinal products.
nevroleptike (npr. fenotiazine, sertindol, sultoprid, klorpromazin, haloperidol, mesoridazin, pimozid ali tioridazin), antidepresive,
Neuroleptics (e.g. phenothiazines, sertindole, sultopride, chlorpromazine, haloperidol, mesoridazine, pimozide, or thioridazine), antidepressive medicinal products.
nevroleptike, (npr. fenotiazin, sertindol, sultoprid, klorpromazin, haloperidol, mesoridazin, pimozid ali tioridazin), antidepresive,
neuroleptics (substances used in the treatment of mental disorders) oral anticoagulants
nevroleptiki (zdravila za zdravljenje duševnih motenj) peroralni antikoagulanti
neuroleptics (substances used in the treatment of mental disorders) oral anticoagulants
nevroleptiki (zdravila za zdravljenje duševnih motenj), peroralni antikoagulanti.
Neuroleptics (used to treat some mental disorders)
nevroleptike (uporabljajo se za zdravljenje nekaterih duševnih motenj)
neuroleptics/antipsychotics (clozapine, haloperidol, phenothiazine), used to treat some mental illnesses
nevroleptiki/antipsihotiki (klozapin, haloperidol, fenotiazin), ki se uporabljajo za zdravljenje nekaterih duševnih bolezni;
Neurologic disorders
Nevrološki neželeni učinki
Neurologic evaluation should be performed in patients with non-infectious intermediate uveitis prior to the initiation of Humira therapy and regularly during treatment to assess for pre- existing or developing central demyelinating disorders.
Pri bolnikih z neinfekcijskim intermediarnim uveitisom je treba pred začetkom zdravljenja z zdravilom Humira in redno med zdravljenjem opravljati nevrološko oceno, da se oceni že obstoječe ali razvijajoče se demielinizirajoče bolezni osrednjega živčevja.
neurologic events: shaking (or tremor), confusion, disturbances of brain function (encephalopathy), difficulty in communicating (aphasia), seizure (convulsion).
nevrološki učinki: tresenje (tremor), zmedenost, moteno delovanje možganov (encefalopatija), težave s sporazumevanjem (afazija), napadi krčev (konvulzije).
Neurological disorders (such as cerebellar symptoms, diplopia, lateral nystagmus, psychomotor slowdown, hand movements and axial hypotonia) have been observed in children who had been voluntarily prescribed more than 2.5 times the maximum recommended dose of 100 mg/kg/day for several years.
Nevrološke motnje (kot so cerebelarni simptomi, diplopija, lateralni nistagmus, upočasnjena pshihomotorika, premikanje rok in aksialna hipotonija) so opazili pri otrocih – prostovoljcih, ki so jim nekaj let predpisovali več kot 2,5-kratni največji priporočen odmerek 100 mg/kg/dan.
Neurological disorders have been observed in children treated with 2.5 to 3 times the recommended dose for several years.
Nevrološke motnje so opazili pri otrocih, ki so jih nekaj let zdravili z 2,5- do 3-kratnim priporočenim odmerkom.
Neurological disorders such as encephalomyelitis (inflammation of the central nervous system), neuritis (inflammation of nerves) and a type of paralysis known a Guillain-Barré Syndrome
Nevrološke motnje, npr. encefalomielitis (vnetje osrednjega živčevja), nevritis (vnetje živcev) in vrsta ohromitve, imenovana Guillain-Barréjev sindrom.
Neurological disorders such as encephalomyelitis (inflammation of the central nervous system), neuritis (inflammation of nerves) and a type of paralysis known as Guillain-Barré Syndrome.
Nevrološke motnje, kot so encefalomielitis (vnetje osrednjega živčevja), nevritis (vnetje živcev) in vrsta paralize, znana kot Guillain-Barréjev sindrom.
Neurological disorders, such as encephalomyelitis, and Guillain Barré syndrome.
Nevrološke bolezni kot so encefalomielitis in Guillain Barréjev sindrom
Neurological disorders, such as encephalomyelitis, neuritis and Guillain Barré syndrome
Nevrološke motnje, kot so encefalomielitis, nevritis in Guillain-Barréjev sindrom.
Neurological disorders, such as encephalomyelitis, neuritis and Guillain Barré syndrome
nevrološke motnje, na primer encefalomielitis, nevritis in Guillain- Barréjev sindrom
Neurological disorders, such as encephalomyelitis, neuritis, and Guillain Barré syndrome.
Nevrološke motnje, kot so encefalomielitis, nevritis in Guillain-Barréjev sindrom.
Neurological disorders, such as neuralgia, paraesthesia, convulsions and neuritis.
Bolesť hlavy, závrat, spavosť, synkopa.
Neurological events
OZNAČEVANJE
Neurological findings, including muscle rigidity, involuntary movements, altered consciousness, mental status changes; other disturbances, such as autonomic dysfunction, tachycardia, tachypnoea, sweating, hyper- or hypotension; laboratory findings, such as creatine phosphokinase elevation, leucocytosis, myoglobinuria, and increased serum myoglobin have been reported.
Poročali so o nevroloških ugotovitvah, vključno s togostjo mišic, nehotenimi gibi, motnjami zavesti, spremembami duševnega stanja; drugih motnjah, kot so disavtonomija, tahikardija, tahipneja, znojenje, hiper- ali hipotenzija; laboratorijskih ugotovitvah, kot so povišana kretin- fosfokinaza, levkocitoza, mioglobinurija in povišan mioglobin v serumu.
neurological infections (including viral meningitis)
nevrološke okužbe (vključno z virusnim meningitisom)
neurological infections (including viral meningitis);
nevrološke okužbe (vključno z virusnim meningitisom);
Neurological movement disorder where your muscles contract causing twisting and repetitive movements or abnormal postures.
edacija, nevrološke motnje gibanja, pri katerih se mišice krčijo, kar povzroča zvijanje in ponavljajoče se gibe ali nenormalno držo.
Neurological problems: Kadcyla can damage nerves.
Nevrološke težave: Zdravilo Kadcyla lahko okvari živce.
neurological reactions: ataxia (lack of coordination) and convulsions.
nevrološke reakcije: ataksija (pomanjkanje koordinacije) in konvulzije;
neurological symptoms, syncope3, hypertonia, dizziness, paraesthesia, seizures, migraine
nevrološki simptomi, sinkopa3, hipertonija, omotica, parestezije, napadi, migrena
Neuromuscular blocking agent
Mišični relaksant
neuromuscular toxicity (including
(vključno z rabdomiolizo) (glejte
neuromuscular toxicity (including
Učinek na koncentracijo zdravila
Neuronal phospholipidosis occurred in dogs dosed for  3 months at lower systemic exposures than those obtained at therapeutic doses in humans.
Pri psih, ki so prejemali odmerke zdravila ≥ 3 mesece, so opažali fosfolipidozo nevronov pri manjših sistemskih izpostavljenostih, kot so jih dobili pri terapevtskih odmerkih pri človeku.
Neuronal phospholipidosis occurred in dogs dosed for  3 months at lower systemic exposures than those obtained at therapeutic doses in humans.
Pri psih, ki so ≥ 3 mesece dobivali odmerke zdravila za manjšo sistemsko izpostavljenost od tiste, dosežene med uporabo terapevtskih odmerkov pri človeku, se je pojavila fosfolipidoza nevronov.
neuropathic pain (pain due to nerve damage), including peripheral neuropathic pain, such as the pain experienced by patients with diabetes or herpes zoster (shingles), and central neuropathic pain, such as the pain experienced by patients who have had a spinal cord injury;
nevropatsko bolečino (bolečino zaradi poškodbe živcev), vključno s periferno nevropatsko bolečino, kot se pojavlja pri bolnikih s sladkorno boleznijo ali pasovcem, in centralno nevropatsko bolečino, kot se pojavlja pri bolnikih s poškodbo hrbtenjače;